FDA Approves Contrast Agent for Pediatric Patients
By MedImaging International staff writers Posted on 12 Sep 2017 |
The US Food and Drug Administration (FDA) has approved the MRI contrast agent gadoterate meglumine for intravenous use in children younger than two years old, as well as neonates.
The agent is used to visualize abnormal vascularity in the Central Nervous System (CNS), and a disrupted Blood Brain Barrier (BBB), and previously had FDA approval only for children older than two.
The agent Dotarem (gadoterate meglumine) is manufactured by Guerbet (Paris, France). Dotarem is an ionic gadolinium-based and macrocyclic contrast medium, and has been approved for use in 79 countries.
The review by the FDA was based on a study of 51 children aged 23 months and less, including neonates, in nine centers. The results of the study showed that the safety, and PharmacoKinetic (PK) profiles, using a standard dose (0.1 mmol/kg), were similar in the study group to those of adults and children more than two years old. The observed safety profile of Dotarem in the study group was consistent with that reported in older patients.
VP North America at Guerbet, Massimo Carrara, said, "It is critical for Guerbet to help patients and their healthcare providers meet this medical need. We are committed to providing safe and effective contrast media to improve diagnosis of all populations including those who need special care, like young children. In fact, a study published earlier this year in Pediatric Radiology found that 80% of children's hospitals surveyed now use macrocyclic contrast agents."
The agent is used to visualize abnormal vascularity in the Central Nervous System (CNS), and a disrupted Blood Brain Barrier (BBB), and previously had FDA approval only for children older than two.
The agent Dotarem (gadoterate meglumine) is manufactured by Guerbet (Paris, France). Dotarem is an ionic gadolinium-based and macrocyclic contrast medium, and has been approved for use in 79 countries.
The review by the FDA was based on a study of 51 children aged 23 months and less, including neonates, in nine centers. The results of the study showed that the safety, and PharmacoKinetic (PK) profiles, using a standard dose (0.1 mmol/kg), were similar in the study group to those of adults and children more than two years old. The observed safety profile of Dotarem in the study group was consistent with that reported in older patients.
VP North America at Guerbet, Massimo Carrara, said, "It is critical for Guerbet to help patients and their healthcare providers meet this medical need. We are committed to providing safe and effective contrast media to improve diagnosis of all populations including those who need special care, like young children. In fact, a study published earlier this year in Pediatric Radiology found that 80% of children's hospitals surveyed now use macrocyclic contrast agents."
Latest MRI News
- World's First Sensor Detects Errors in MRI Scans Using Laser Light and Gas
- Diamond Dust Could Offer New Contrast Agent Option for Future MRI Scans
- Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients
- PET/MRI Improves Diagnostic Accuracy for Prostate Cancer Patients
- Next Generation MR-Guided Focused Ultrasound Ushers In Future of Incisionless Neurosurgery
- Two-Part MRI Scan Detects Prostate Cancer More Quickly without Compromising Diagnostic Quality
- World’s Most Powerful MRI Machine Images Living Brain with Unrivaled Clarity
- New Whole-Body Imaging Technology Makes It Possible to View Inflammation on MRI Scan
- Combining Prostate MRI with Blood Test Can Avoid Unnecessary Prostate Biopsies
- New Treatment Combines MRI and Ultrasound to Control Prostate Cancer without Serious Side Effects
- MRI Improves Diagnosis and Treatment of Prostate Cancer
- Combined PET-MRI Scan Improves Treatment for Early Breast Cancer Patients
- 4D MRI Could Improve Clinical Assessment of Heart Blood Flow Abnormalities
- MRI-Guided Focused Ultrasound Therapy Shows Promise in Treating Prostate Cancer
- AI-Based MRI Tool Outperforms Current Brain Tumor Diagnosis Methods
- DW-MRI Lights up Small Ovarian Lesions like Light Bulbs